Citations Report
Citations Report - Cardiovascular Pharmacology: Open Access [77 Articles]
The articles published in Cardiovascular Pharmacology: Open Access have been cited 77 times by eminent researchers all around the world. Following is the list of articles that have cited the articles published in Cardiovascular Pharmacology: Open Access.
Hassan M, Ellahham S, Ibrahim HS (2019) Frailty in Heart Failure: A Coalesce of International Guidelines. J Clin Exp Cardiolog 10:2. |
|
Wong CK (2016) From Arctic to Antarctic: Is There any Remaining Role for Platelet Function Testing to Tailor Therapy after Coronary Stent Implantation. Cardiovasc Pharm Open Access 5: e132. |
|
Wong CK (2015) Time for a Reappraisal: How much has the Last 10 Years of Mainstream STEMI Research Impacted on STEMI Outcome?. Cardiovascular Pharmacology: Open Access. |
|
Kang YC, Chen MH, Wang LY, Huang MP (2013) Cardiotoxicity Induced by a Single Oral Therapeutic Dose of Verapamil in a Patient with End-Stage Renal Disease and Liver Cirrhosis. Acta Nephrologica 27: 225-230. |
|
é»ä¾å©·, ææ è³, æ´æå¿, å³æç¿°, ææ£å¸¸ (2015) 宿¬¡é»åéåå°å¹´è¼è¥èç·æ§åèç¡¬åææ¨çå½±é¿. 大å°é«è²å¸å 17:96-107. |
|
Kotani K (2016) Plasma lipoprotein-associated phospholipase A2 levels correlated with the cardio-ankle vascular index in long-term type 2 diabetes mellitus patients. International journal of molecular sciences 17: 634. |
|
Sorokin A, Kotani K, Bushueva O, Taniguchi N, Lazarenko V (2015) The cardio-ankle vascular index and ankle-brachial index in young Russians. J Atheroscler Thromb 22: 211-218. |
|
Parsons XH (2016) Human pluripotent stem cell-based PluriXcel technology platforms provide stem cell treatment development and manufacturing innovations for progressing to the clinic. J Regen Ther 1: 1-8. |
|
Parsons XH (2013) The designation of human cardiac stem cell therapy products for human trials. J Clin Trial Cardiol 1: 02. |
|
Parsons XH (2014) The openness of pluripotent epigenome–defining the genomic integrity of stemness for regenerative medicine. Int J Cancer Ther Oncol 2: 20114. |
|
Parsons XH (2016) Direct conversion of pluripotent human embryonic stem cells under defined culture conditions into human neuronal or cardiomyocyte cell therapy derivatives. Human Embryonic Stem Cell Protocols 299-318. |
|
Parsons XH (2016) Journal of Regenerative Therapeutics Volume 1, Issue 1, October 2016, Pages 1–8. Journal of Regenerative Therapeutics. 1 : 1-8. |
|
Parsons XH (2016) Human pluripotent stem cell-based PluriXcel technology platforms provide stem cell treatment development and manufacturing innovations for progressing to the clinic. J Regen Ther 1: 1-8. |
|
Parsons XH (2013) The designation of human cardiac stem cell therapy products for human trials. J Clin Trial Cardiol 1: 02. |
|
Parsons XH (2014) The openness of pluripotent epigenome–defining the genomic integrity of stemness for regenerative medicine. Int J Cancer Ther Oncol 2: 20114. |
|
Parsons XH (2016) Direct conversion of pluripotent human embryonic stem cells under defined culture conditions into human neuronal or cardiomyocyte cell therapy derivatives. Human Embryonic Stem Cell Protocols 16: 299-318. |
|
Brown SA, Nhola L, Herrmann J (2016) Cardiovascular Toxicities of Small Molecule TKIs: An Opportunity for SystemsâBased Approaches. Clinical Pharmacology & Therapeutics. |
|
Yaniv Y, Ahmet I, Tsutsui K, Behar J, Moen JM, et al. (2016) Deterioration of autonomic neuronal receptor signaling and mechanisms intrinsic to heart pacemaker cells contribute to ageâassociated alterations in heart rate variability in vivo. Aging cell 15: 716-724. |
|
Yaniv Y, Ahmet I, Liu J, Lyashkov AE, Guiriba TR, et al. (2016) Synchronization of sinoatrial node pacemaker cell clocks and its. |
|
Captur G, Karperien AL, Hughes AD, Francis DP, Moon JC (2016) The fractal heart [mdash] embracing mathematics in the cardiology clinic. Nature Reviews Cardiology. |
|